Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Jeet will be a trusted partner in cardiovascular care
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
Subscribe To Our Newsletter & Stay Updated
